M. De-traitement-de-la-douleur-toulouse-cedex-;-anne-dumolard, C. De-grenoble-hopital-sud-clinique-pierre-yves-hatron, M. , C. De-lille-hopital, and C. Huriez, Echirolles Cedex Service de Medecine Interne and Pharmacie Centrale, Lille Cedex; Serge Perrot, MD PhD, essais cliniques and Service de Rhumatologie-Unite de recherche clinique P.R.E.D.O. S, Amiens Cedex

. Spain-alegre and P. Md, Servicio de Reumatologia and Servicio de Farmacia Planta Sotano, Pabellon A, Hospital Universitario Carlos Haya, Pabellon Hospital Civil, Malaga; Juan Gómez-Reino, MD, PhD, Servicio de Reumatologia Hospital Clinico and Servicio de Farmacia, planta-4 Hospital, de Reumatologia Hospital Central de Asturias and Servicio de Farmacia, planta -4 Hospital Central de Asturias

A. Rodríguez-de-la-serna, M. Servicio-de-reumatologia, . Hospital-de-la-santa-creu-i-sant-pau, . T. Barcelona, . Netherlands et al., Newcastle upon Tyne United States: Patrick Fatigue Consultation Clinic, Oregon Health & Science University Research and OHSU Research PharmacyPinnacle Research

W. George, M. Research, M. Greenwald, M. Medex-healthcare, and . Research, Inc, at Great Lakes Family Care Cardillac

L. Perez-limonte, M. , A. Research-inc, F. Miami, M. Ronald et al., Advanced Clinical Research Institute Victor Rosenfeld, MD, Sansum Clinic and Sleep Med-Encina Lodge Apex Research Institute, MD (Initial PI was Robert Schreiman, MD)

E. Walko, . Do, . Advanced-pain, &. Management, . Rehabilitation et al., Author details 1, Northridge Neurological Research

F. Wolfe, H. Smythe, M. Yunus, R. Bennett, C. Bombardier et al., The american college of rheumatology 1990 criteria for the classification of fibromyalgia, Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee, pp.160-172, 1990.
DOI : 10.1002/art.1780330203

F. Wolfe, D. Clauw, M. Fitzcharles, D. Goldenberg, R. Katz et al., The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity, Arthritis Care & Research, vol.68, issue.Suppl, pp.600-610, 2010.
DOI : 10.1002/acr.20140

A. Jain, B. Carruthers, M. Van-de-sande, S. Barron, C. Donaldson et al., Fibromyalgia Syndrome: Canadian Clinical Working Case Definition, Diagnostic and Treatment Protocols???A Consensus Document, Journal of Musculoskeletal Pain, vol.11, issue.4, pp.3-107, 2003.
DOI : 10.1300/J094v11n04_02

F. Wolfe, K. Ross, J. Anderson, I. Russell, and L. Hebert, The prevalence and characteristics of fibromyalgia in the general population, Arthritis & Rheumatism, vol.14, issue.Suppl 9, pp.19-28, 1995.
DOI : 10.1002/art.1780380104

F. Wolfe, J. Anderson, D. Harkness, R. Bennett, X. Caro et al., Health status and disease severity in fibromyalgia. Results of a six-center longitudinal study, Arthritis & Rheumatism, vol.23, issue.9, pp.1571-1579, 1997.
DOI : 10.1002/art.1780400905

A. De-miquel and C. , Fibromialgia: enfermedad de la emoci??n o emoci??n del dolor, Medicina Cl??nica, vol.131, issue.13, pp.503-504, 2008.
DOI : 10.1157/13127286

P. Mease, L. Arnold, E. Choy, D. Clauw, L. Crofford et al., Fibromyalgia Syndrome Module at OMERACT 9: Domain Construct, The Journal of Rheumatology, vol.36, issue.10, pp.2318-2329, 2009.
DOI : 10.3899/jrheum.090367

E. Choy and P. Mease, Key Symptom Domains to Be Assessed in Fibromyalgia (Outcome Measures in Rheumatoid Arthritis Clinical Trials), Rheumatic Disease Clinics of North America, vol.35, issue.2
DOI : 10.1016/j.rdc.2009.05.002

S. Perrot, D. Bouhassira, J. Fermanian, and C. D. , Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST), Pain, vol.150, issue.2, pp.250-256, 2010.
DOI : 10.1016/j.pain.2010.03.034

L. Arnold, B. Emir, T. Murphy, B. Zeiher, L. Pauer et al., Safety Profile and Tolerability of Up to 1 Year of Pregabalin Treatment in 3 Open-Label Extension Studies in Patients With Fibromyalgia, Clinical Therapeutics, vol.34, issue.5, pp.1092-1102, 2012.
DOI : 10.1016/j.clinthera.2012.03.003

J. Branco, C. P. Montagne, A. Bouroubi, and A. , Longterm Therapeutic Response to Milnacipran Treatment for Fibromyalgia. A European 1-Year Extension Study Following a 3-Month Study, The Journal of Rheumatology, vol.38, issue.7, pp.1403-1412, 2011.
DOI : 10.3899/jrheum.101025

A. Chappell, G. Littlejohn, D. Kajdasz, M. Scheinberg, D. Souza et al., A 1-year Safety and Efficacy Study of Duloxetine in Patients With Fibromyalgia, The Clinical Journal of Pain, vol.25, issue.5, pp.365-375, 2009.
DOI : 10.1097/AJP.0b013e31819be587

P. Mease, I. Russell, D. Kajdasz, C. Wiltse, M. Detke et al., Long-Term Safety, Tolerability, and Efficacy of Duloxetine in the Treatment of Fibromyalgia, Seminars in Arthritis and Rheumatism, vol.39, issue.6, pp.454-464, 2010.
DOI : 10.1016/j.semarthrit.2008.11.001

D. Goldenberg, D. Clauw, R. Palmer, P. Mease, W. Chen et al., Durability of Therapeutic Response to Milnacipran Treatment for Fibromyalgia. Results of a Randomized, Double-Blind, Monotherapy 6-Month Extension Study, Pain Medicine, vol.11, issue.2, pp.180-194, 2010.
DOI : 10.1111/j.1526-4637.2009.00755.x

W. Hauser, K. Thieme, and D. Turk, Guidelines on the management of fibromyalgia syndrome - A systematic review, European Journal of Pain, vol.40, issue.57, pp.5-10, 2010.
DOI : 10.1016/j.ejpain.2009.01.006

W. Hauser, F. Petzke, N. Uceyler, and C. Sommer, Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis, Rheumatology, vol.50, issue.3, pp.532-543, 2011.
DOI : 10.1093/rheumatology/keq354

B. Nishishinya, G. Urrutia, B. Walitt, A. Rodriguez, X. Bonfill et al., Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy, Rheumatology, vol.47, issue.12, pp.1741-1746, 2008.
DOI : 10.1093/rheumatology/ken317

W. Hauser, F. Petzke, and C. Sommer, Comparative Efficacy and Harms of Duloxetine, Milnacipran, and Pregabalin in Fibromyalgia Syndrome, The Journal of Pain, vol.11, issue.6, pp.505-521, 2007.
DOI : 10.1016/j.jpain.2010.01.002

W. Hauser, G. Urrutia, S. Tort, N. Uceyler, and B. Walitt, Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome, Cochrane Database Syst Rev, vol.10, issue.8, p.10292, 2013.
DOI : 10.1002/14651858.CD010292

B. Walitt, M. Fitzcharles, A. Hassett, R. Katz, W. Hauser et al., The Longitudinal Outcome of Fibromyalgia: A Study of 1555 Patients, The Journal of Rheumatology, vol.38, issue.10, pp.2238-2246, 2011.
DOI : 10.3899/jrheum.110026

J. Black, D. Pardi, C. Hornfeldt, and N. Inhaber, The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy, Sleep Medicine, vol.10, issue.8, pp.829-835, 2009.
DOI : 10.1016/j.sleep.2009.05.004

J. Black, D. Pardi, C. Hornfeldt, and N. Inhaber, The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy, J Clin Sleep Med, vol.6, pp.596-602, 2010.

H. Moldofsky, N. Inhaber, D. Guinta, and S. Alvarez-horine, Effects of Sodium Oxybate on Sleep Physiology and Sleep/Wake-related Symptoms in Patients with Fibromyalgia Syndrome: A Double-blind, Randomized, Placebo-controlled Study, The Journal of Rheumatology, vol.37, issue.10, pp.2156-2166, 2010.
DOI : 10.3899/jrheum.091041

I. Russell, A. Perkins, and J. Michalek, Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: A randomized, double-blind, placebo-controlled, multicenter clinical trial, Arthritis & Rheumatism, vol.40, issue.1, pp.299-309, 2009.
DOI : 10.1002/art.24142

E. Choy, C. Alegre, P. Sarzi-puttini, R. Van-seventer, Y. Wang et al., Sodium Oxybate in Fibromyalgia 06?009 Study Group: The effects of sodium oxybate on sleep disturbance, fatigue, and functioning in fibromyalgia: results from a phase 3, randomized, double-blind, placebo-controlled international trial [abstract], Ann Rheum Dis, vol.69, p.449, 2010.

I. Russell, A. Holman, T. Swick, S. Alvarez-horine, Y. Wang et al., Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: Results from a 14-week, randomized, double-blind, placebo-controlled study, Pain, vol.152, issue.5, pp.1007-1017, 2011.
DOI : 10.1016/j.pain.2010.12.022

M. Spaeth, R. Bennett, B. Benson, Y. Wang, C. Lai et al., Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial, Annals of the Rheumatic Diseases, vol.71, issue.6, pp.935-942, 2012.
DOI : 10.1136/annrheumdis-2011-200418

R. Dworkin, D. Turk, J. Farrar, J. Haythornthwaite, M. Jensen et al., Core outcome measures for chronic pain clinical trials: IMMPACT recommendations, Pain, vol.113, issue.1, pp.9-19, 2005.
DOI : 10.1016/j.pain.2004.09.012

R. Bennett, A. Bushmakin, J. Cappelleri, G. Zlateva, and A. Sadosky, Minimal Clinically Important Difference in the Fibromyalgia Impact Questionnaire, The Journal of Rheumatology, vol.36, issue.6, pp.1304-1311, 2009.
DOI : 10.3899/jrheum.081090

D. Sheehan, Y. Lecrubier, K. Sheehan, P. Amorim, J. Janavs et al., The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, J Clin Psychiatry, vol.59, pp.22-33, 1998.

A. Beck, R. Steer, and G. Brown, San Antonio: The Psychological Corporation, 1996.

C. Burckhardt, S. Clark, and R. Bennett, The fibromyalgia impact questionnaire: development and validation, pp.728-733, 1991.

W. Guy, ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare publication

J. Ware, . Jr, and C. Sherbourne, The MOS 36-ltem Short-Form Health Survey (SF-36), Medical Care, vol.30, issue.6, pp.473-483, 1992.
DOI : 10.1097/00005650-199206000-00002

T. Weaver, A. Laizner, L. Evans, G. Maislin, D. Chugh et al., An instrument to measure functional status outcomes for disorders of excessive sleepiness, pp.835-843, 1997.

L. Carter, D. Pardi, J. Gorsline, and R. Griffiths, Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem??): Differences in characteristics and misuse, Drug and Alcohol Dependence, vol.104, issue.1-2, pp.1-10, 2009.
DOI : 10.1016/j.drugalcdep.2009.04.012

C. Burckhardt, O. Reilly, C. Wiens, A. Clark, S. Campbell et al., Assessing depression in fibromyalgia patients, Arthritis Care & Research, vol.239, issue.1, pp.35-39, 1994.
DOI : 10.1002/art.1790070108

A. Kassam and S. Patten, Major depression, fibromyalgia and labour force participation: A population-based cross-sectional study, BMC Musculoskeletal Disorders, vol.17, issue.1, 2006.
DOI : 10.1016/S1521-6942(03)00034-2

L. Dreyer, S. Kendall, B. Danneskiold-samsøe, E. Bartels, and H. Bliddal, Mortality in a cohort of Danish patients with fibromyalgia: Increased frequency of suicide, Arthritis & Rheumatism, vol.61, issue.Suppl 9, pp.3101-3108, 2010.
DOI : 10.1002/art.27623

E. Calandre, J. Vilchez, R. Molina-barea, M. Tovar, J. Garcia-leiva et al., Suicide attempts and risk of suicide in patients with fibromyalgia: a survey in Spanish patients, Rheumatology, vol.50, issue.10, pp.1889-1893, 2011.
DOI : 10.1093/rheumatology/ker203

F. Wolfe, A. Hassett, B. Walitt, and K. Michaud, Mortality in fibromyalgia: A study of 8,186 patients over thirty-five years, Arthritis Care & Research, vol.341, issue.Suppl 51, pp.94-101, 2011.
DOI : 10.1002/acr.20301

A. Husain, R. Ristanovic, and R. Bogan, Weight loss in narcolepsy patients treated with sodium oxybate, Sleep Medicine, vol.10, issue.6, pp.661-663, 2009.
DOI : 10.1016/j.sleep.2008.05.012

J. Farrar, Y. Pritchett, M. Robinson, A. Prakash, and A. Chappell, The Clinical Importance of Changes in the 0 to 10 Numeric Rating Scale for Worst, Least, and Average Pain Intensity: Analyses of Data from Clinical Trials of Duloxetine in Pain Disorders, The Journal of Pain, vol.11, issue.2, pp.109-118, 2010.
DOI : 10.1016/j.jpain.2009.06.007

L. Arnold, R. Gendreau, R. Palmer, J. Gendreau, and Y. Wang, Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: Results of a randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, vol.11, issue.Suppl 2, pp.2745-2756, 2010.
DOI : 10.1002/art.27559

J. Branco, O. Zachrisson, S. Perrot, and Y. Mainguy, A European Multicenter Randomized Double-blind Placebo-controlled Monotherapy Clinical Trial of Milnacipran in Treatment of Fibromyalgia, The Journal of Rheumatology, vol.37, issue.4, pp.851-859, 2010.
DOI : 10.3899/jrheum.090884

D. Clauw, P. Mease, R. Palmer, R. Gendreau, and Y. Wang, Milnacipran for the treatment of fibromyalgia in adults: A 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial, Clinical Therapeutics, vol.30, issue.11, pp.1988-2004, 2008.
DOI : 10.1016/j.clinthera.2008.11.009

M. Geisser, R. Palmer, R. Gendreau, Y. Wang, and D. Clauw, A Pooled Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials of Milnacipran Monotherapy in the Treatment of Fibromyalgia, Pain Practice, vol.60, issue.10, pp.120-131, 2011.
DOI : 10.1111/j.1533-2500.2010.00403.x

P. Mease, D. Clauw, R. Gendreau, S. Rao, J. Kranzler et al., The Efficacy and Safety of Milnacipran for Treatment of Fibromyalgia. A Randomized, Double-blind, Placebo-controlled Trial, The Journal of Rheumatology, vol.36, issue.2, pp.398-409, 2009.
DOI : 10.3899/jrheum.080734